Saturday, February 16, 2008
Those healthcare "reformers" out there who denounce the pharmaceutical industry's supposedly wasteful investments in "me-too" drugs or new indications for old drugs ought to reflect on the impact of superficially minor tweaks to therapies for autoimmune diseases. Patients crippled by multiple sclerosis, Crohn's, or rheumatoid arthritis have good reason to be grateful for incrementalism.
Amen. You can add psychiatric medications to that list. Similar medications can have different side-effect profiles, and having a menu is a blessing for sufferers in the long run. At a minimum, one can at least choose which side-effects one is willing to endure, and that control is a great gift.
I suppose if the anti-pharma people prefer, they can just let folks suffer.